Overview of External Investment - Guizhou Yongji Printing Co., Ltd. approved an external investment agreement on January 26, 2025, to acquire 100% equity of Phytoca Holdings through its wholly-owned subsidiary Yongji Health Pty Ltd, with an investment amount of approximately AUD 62.2951 million (about RMB 282 million) [3][4]. Progress of External Investment - The first phase of equity transfer was completed on April 7, 2025, with Yongji Health holding 60% of Phytoca Holdings, which will be included in the company's consolidated financial statements [5][6]. Second Phase Equity Purchase Price Determination - The purchase price for the second phase is not fixed but will be dynamically adjusted based on Phytoca Holdings' audited EBIT for the fiscal year 2025 [7][8]. - The audited EBIT for Phytoca Holdings for the fiscal year 2025 was AUD 8,481,083.16 (approximately RMB 41 million) [9][11]. Calculation of Second Phase Purchase Price - The final purchase price for the second phase was determined to be AUD 38,509,532.35 (approximately RMB 187 million), which is higher than the expected purchase price of AUD 20,781,482.40 (approximately RMB 101 million) [10][11]. - The increase in the purchase price was due to the actual audited EBIT exceeding initial expectations by AUD 246,220 [11]. Subsequent Arrangements - The funding for the second phase equity acquisition will consider self-funding, self-raised funds, and other financing channels. The company plans to apply for a merger loan of RMB 100 million to support the acquisition [12][13]. Impact of External Investment and Merger Loan - The acquisition is a crucial part of the company's external investment strategy, enhancing its presence in the regulated pharmaceutical market in Australia and improving long-term profitability and competitiveness [18]. - The merger loan application is expected to optimize the company's financing structure and support the acquisition without posing significant financial risks [19].

Core Viewpoint - The company has made a strategic investment in Chongqing Sangui Animation Technology Co., Ltd., acquiring a 51% stake, which marks its entry into the software and information technology services sector [1] Group 1: Investment in Animation Technology - The investment in Chongqing Sangui Animation Technology focuses on AI animation, which is expected to have significant growth potential due to the integration of AI technology in content creation [2] - The collaboration with major platforms like Tencent and Douyin is anticipated to provide support for AI animation, making it a potential new content trend following live-action short dramas [2] Group 2: Regulated Pharmaceutical Business - The company is concentrating on the Australian market for its regulated pharmaceutical business, with a stable supply from its cultivation base in Tasmania [3] - The acquisition of Phytoca Holdings is expected to enhance the sales network and product structure of the regulated pharmaceutical business, with revenue from this segment doubling year-on-year in the first half of 2025 [3] Group 3: Premium Paper Packaging Business - The premium paper packaging business, primarily focused on cigarette labels and wine boxes, has established a strong market position through advanced anti-counterfeiting technologies [4] - The collaboration with Guizhou Zhongyan has been stable since 2007, with revenue from this client projected to account for 66.14% in 2024, while new clients are being developed to further enhance revenue [4] Group 4: Overall Business Outlook - The company's diverse business segments are expected to provide stable cash flow, supporting the growth of emerging sectors like AI animation and regulated pharmaceuticals [5] - Revenue projections for 2025-2027 indicate a growth trajectory, with expected revenues of 1.008 billion, 1.228 billion, and 1.475 billion yuan, reflecting year-on-year growth rates of 11.35%, 21.86%, and 20.14% respectively [5]